Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy

Stem Cells Translational Medicine

Volumn 2, Issue 4, 2013, Pages 274-283

  Knorr, David A ^a,b   Ni, Zhenya ^a,b   Hermanson, David ^a,b   Hexum, Melinda K ^a,b   Bendzick, Laura ^a,b   Cooper, LAURENCE J N ^c,d   Lee, Dean A ^c,d   Kaufman, Dan S ^a,b,e  

^a and Transplant) ^*  (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Hematopoiesis; Hematopoietic cells and bull; Immunotherapy and bull; Lymphocytes and bull; Pluripotent stem cells and bull

Indexed keywords

5' NUCLEOTIDASE; CD16 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD94 ANTIGEN; GAMMA INTERFERON; INHIBITOR OF DIFFERENTIATION 2; INTERLEUKIN 15; INTERLEUKIN 21; INTERLEUKIN 3; INTERLEUKIN 7; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LEUKOSIALIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL KILLER CELL RECEPTOR NKG2D; TRANSCRIPTION FACTOR E2A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER THERAPY; CELL ASSAY; CELL DIFFERENTIATION; CELL EXPANSION; CELL SELECTION; CYTOTOXICITY; EMBRYOID BODY; EMBRYONIC STEM CELL; FLOW CYTOMETRY; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLURIPOTENT STEM CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84876250402     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2012-0084     Document Type: Article

References (28)

1. Ljunggren H-G, Malmberg K-J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007;7:329- 339.
2. Miller JS, Soignier Y, Panoskaltsis-Mortari A et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105:3051- 3057.
3. Rosenberg SA, Restifo NP, Yang JC et al. Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299-308.
4. Galic Z, Kitchen SG, Kacena A et al. T lineage differentiation from human embryonic stem cells. Proc Natl Acad Sci USA 2006;103: 11742-11747.
5. Timmermans F, Velghe I, Vanwalleghem L et al. Generation of T cells from human embryonic stem cell-derived hematopoietic zones. J Immunol 2009;182:6879-6888.
6. Woll PS, Martin CH, Miller JS et al. Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity. J Immunol 2005;175:5095-5103.
7. Ni Z, Knorr DA, Clouser CL et al. Human pluripotent stem cells produce natural killer cells that mediate anti-HIV-1 activity by utilizing diverse cellular mechanisms. J Virol 2011; 85:43-50.
8. Woll PS, Grzywacz B, Tian X et al. Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood 2009;113:6094-6101.
9. Hill KL, Obrtlikova P, Alvarez DF et al. Human embryonic stem cell-derived vascular progenitor cells capable of endothelial and smooth muscle cell function. Exp Hematol 2010;38:246-257.
10. Tian X, Hexum MK, Penchev VR et al. Bioluminescent imaging demonstrates that transplanted human embryonic stem cell-derived CD34+ cells preferentially develop into endothelial cells. STEM CELLS 2009;27:2675-2685.
11. Denman CJ, Senyukov VV, Somanchi SS et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One 2012;7:e30264.
12. Ledran MH, Krassowska A, Armstrong L et al. Efficient hematopoietic differentiation of human embryonic stem cells on stromal cells derived from hematopoietic niches. Cell Stem Cell 2008;3:85-98.
13. Choi KD, Yu J, Smuga-Otto K et al. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. STEM CELLS 2009;27:559-567.
14. Ng ES, Davis R, Stanley EG et al. A protocol describing the use of a recombinant protein-based, animal product-free medium (APEL) for human embryonic stem cell differentiation as spin embryoid bodies. Nat Protoc 2008;3:768-776.
15. Ng ES, Davis RP, Azzola L et al. Forced aggregation of defined numbers of human embryonic stem cells into embryoid bodies fosters robust, reproducible hematopoietic differentiation. Blood 2005;106:1601-1603.
16. Kopher RA, Penchev VR, Islam MS et al. Human embryonic stem cell-derived CD34+ cells function as MSC progenitor cells. Bone 2010;47:718-728.
17. Mrózek E, Anderson P, Caligiuri M. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 1996;87: 2632-2640.
18. Carson WE, Fehniger TA, Haldar S et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 1997;99:937-943.
19. Kim S, Poursine-Laurent J, Truscott SM et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005;436:709-713.
20. Fujisaki H, Kakuda H, Shimasaki N et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009;69:4010-4017.
21. Kaufman DS. Toward clinical therapies utilizing hematopoietic cells derived from human pluripotent stem cells. Blood 2009;114: 3513-3523.
22. Cooley S, Weisdorf DJ, Guethlein LA et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010;116:2411-2419.
23. Porter DL, Levine BL, Kalos M et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New Engl J Med 2011;365:725-733.
24. Torikai H, Reik A, Liu PQ et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 2012;119: 5697-5705.
25. Knorr DA, Kaufman DS. Pluripotent stem cell-derived natural killer cells for cancer therapy. Transl Res 2010;156:147-154.
26. Sadelain M, Brentjens R, Rivie I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009;21: 215-223.
27. Schwartz SD, Hubschman JP, Heilwell G et al. Embryonic stem cell trials for macular degeneration: A preliminary report. Lancet 2012; 379:713-720.
28. Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature 2012;481:295-305.